Importantly, since a direct connection between R-loops and cancer has been recognised [108], WRNIP1 could be employed as a target to further sensitise cancer cells to inhibitors of ATR or CHK1 that are currently under clinical evaluation. The gene discussed is CHEK1; the disease is cancer.